Intervention Review

You have free access to this content

Low dose naltrexone for induction of remission in Crohn's disease

  1. Dan Segal1,
  2. John K MacDonald2,
  3. Nilesh Chande3,*

Editorial Group: Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group

Published Online: 21 FEB 2014

Assessed as up-to-date: 28 FEB 2013

DOI: 10.1002/14651858.CD010410.pub2


How to Cite

Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010410. DOI: 10.1002/14651858.CD010410.pub2.

Author Information

  1. 1

    London Health Sciences Centre - University Hospital, London, Ontario, Canada

  2. 2

    Robarts Research Institute, Robarts Clinical Trials, London, Ontario, Canada

  3. 3

    London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

*Nilesh Chande, London Health Sciences Centre - Victoria Hospital, Room E6-321A, 800 Commissioners Road East, London, Ontario, N6A 5W9, Canada. nilesh.chande@lhsc.on.ca. nchande2@uwo.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 21 FEB 2014

SEARCH

[Figure 1]
Figure 1. Flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Low dose naltrexone versus placebo, outcome: 1.1 Clinical remission (CDAI < 150).
[Figure 4]
Figure 4. Forest plot of comparison: 1 Low dose naltrexone versus placebo, outcome: 1.2 Clinical response (CDAI change of 70 or greater).
[Figure 5]
Figure 5. Forest plot of comparison: 1 Low dose naltrexone versus placebo, outcome: 1.6 Endoscopic response.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Low dose naltrexone versus placebo, outcome: 1.8 Specific adverse events.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Low dose naltrexone versus placebo, Outcome 1 Clinical remission (CDAI < 150).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Low dose naltrexone versus placebo, Outcome 2 Clinical response (CDAI change of 70 or greater).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Low dose naltrexone versus placebo, Outcome 3 Clinical response (CDAI change of 100 or greater).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Low dose naltrexone versus placebo, Outcome 4 Endoscopic remission (CDEIS less than 3).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Low dose naltrexone versus placebo, Outcome 5 Endoscopic remission (CDEIS less than 6).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Low dose naltrexone versus placebo, Outcome 6 Endoscopic response.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Low dose naltrexone versus placebo, Outcome 7 Withdrawals due to adverse events.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Low dose naltrexone versus placebo, Outcome 8 Specific adverse events.